Phone
800.277.1193
Judge Blocks Proposed Elmiron Class Action
A federal judge has blocked the class action lawsuit proposed in Almond v. Janssen Pharmaceuticals, wherein the plaintiff had not yet suffered injury from the defendant’s drug, but rather demanded compensation for medical monitoring to check for signs of damage from the medication.
Elmiron: A Failure of Vision
An explosion of recent studies from multiple university medical centers recently exposed that the use of the prescription drug Elmiron® can result in patients’ vision failure, up to and including legal blindness. Elmiron® is the brand name for pentosane polysulfate sodium (“PPS”), a drug manufactured and distributed by Janssen Pharmaceuticals. It has been marketed for nearly twenty-five years and resulted in billions of dollars of sales for Janssen. The earliest clinical trials for Elmiron® from the 1990s revealed not only dubious efficacy, but also a hos
Lawsuits for Vision Problems Caused by Elmiron
With 80 product liability lawsuits already filed and hundreds more likely to follow, lawyers are discussing the coordination of multi-district litigation (MDL). To date, legal action has been taken against Johnson & Johnson’s Janssen Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., and other pharma companies.
Plaintiffs allege that these companies knowingly withheld risks connected with long-term use of the drug. Complaints list such outcomes as retinal damage and blurred and distorted vision.